Annalee Armstrong

Ottawa

Senior Editor at BioSpace

Ex-pat Canadian from B.C.'s East Kootenay. I like puppies & wine | Senior Editor @BioSpace, formerly of @FierceBiotech

Featured in: Favicon

fiercebiotech.com Favicon

spglobal.com Favicon

fiercepharma.com Favicon

geneticliteracyproject.org Favicon

clinicalleader.com Favicon

coalage.com Favicon

ramaonhealthcare.com Favicon

biospace.com

linkedin.com Favicon

newsbreak.com + 1 more

Articles

Unusual New Fund Launches to Unlock Some $30B of Capital ‘Trapped’ in Public Biotechs

6 days ago | biospace.com | Annalee Armstrong

Taking a page out of the private equity playbook, a new fund has emerged to recycle over $30 billion of capital “trapped” in failed public biotechs. London-based Alis Biosciences launched on Friday with a pledge to return to shareholders capital that’s invested in publicly listed companies that have suffered a clinical failure or other stumbling block, with nowhere to turn. The plan—which is carefully laid out in three different structures—is a familiar tactic in the private equity world.
Here Today, Gone Tomorrow: Trump’s Policies Give Biopharma Whiplash

1 week ago | biospace.com | Jef Akst |Heather McKenzie |Annalee Armstrong

The uncertainty that came with Donald Trump’s electoral victory in November has only compounded now that he’s in office. Similar question marks have surrounded Robert F. Kennedy Jr., whose anti-vaccine rhetoric and overall criticism of agencies within the Department of Health and Human Services he now heads were potential concerns for the biopharma industry from the first rumors that he’d be Trump’s nominee for HHS secretary.
Biotech’s Next Phase Will Be All-American: Pitchbook

1 week ago | biospace.com | Annalee Armstrong

After the COVID-19 pandemic and a two-year market correction, biotech’s next era will be all about America-first to match protectionist trade policies and other policy shifts to accelerate homegrown manufacturing, Pitchbook said in a new report.
Tariff Turmoil, FDA’s Future, Pfizer’s Obesity Setback and CEO Salaries Revealed

1 week ago | biospace.com | Heather McKenzie |Jef Akst |Annalee Armstrong |Dan Samorodnitsky

> Listen on Spotify> Listen on Apple Products> Listen on Amazon Music> Listen on iHeartIt’s all about tariffs again this week. No sooner had Donald Trump announced that “major” tariffs on the pharmaceutical industry would be coming “very shortly”—sending stocks spiraling—the president announced a 90-day pause on most taxes for imports from countries not named China. But this respite was not to last.
J&J Sets Tariff Tone as Q1 Earnings Begin To Roll In

1 week ago | biospace.com | Annalee Armstrong

Johnson & Johnson kicked off the first quarter earnings period on Tuesday, sending a slight sigh of relief across the industry. That’s because the company only reported modest impacts from the ongoing tariff uncertainty, which analysts have predicted will be the elephant in the room on the industry’s calls this quarter. Indeed, although J&J executives spoke for 37 minutes before addressing tariffs, it was the first question out of the gate when the call pivoted to Q&A.
J&J CEO Duato Urges Tax Fix, Not Tariffs To Drive US Pharma Manufacturing

1 week ago | biospace.com | Annalee Armstrong

Johnson & Johnson CEO Joaquin Duato urged President Donald Trump to consider tax policy changes to encourage more U.S. manufacturing of pharmaceuticals—rather than enacting tariffs that could greatly cut into the company’s profits. “If what you want is to build manufacturing capacity in the U.S., both in medtech and in pharmaceuticals, the most effective answer is not tariffs, but tax policy,” Duato told investors on J&J’s first-quarter earnings call Tuesday morning.
J&J Beats Q1 Analyst Estimates Thanks To Tremfya, Carvykti, While Stelara Fades

1 week ago | biospace.com | Annalee Armstrong

Johnson & Johnson’s medicines, including Tremfya and Carvykti, helped drive a worldwide sales increase of 2.4% in the first quarter, the company reported Tuesday morning. As always, J&J was the first out the gate for pharma earnings, reporting sales of $21.9 billion and diluted earnings per share of $4.54. The medicines unit provided $13.9 billion while the medtech unit kicked in the remaining $8 billion.
Viking Rises as Pfizer’s Oral Obesity Med Falters

1 week ago | biospace.com | Annalee Armstrong

The loss of Pfizer’s oral GLP-1 is Viking Therapeutics’ gain, as the small obesity biotech’s shares rose 13% on the discontinuation of the Big Pharma’s rival medicine. “In our view, Pfizer’s setback comes as an invigorating development for Viking’s shareholders,” William Blair analysts said in a Monday morning note. The New York pharma made the decision to halt development of danuglipron after a participant in a trial experienced signs of liver injury.
Biotech Leaders Implore Sen. Cassidy To Step Up in Wake of FDA Cuts

2 weeks ago | biospace.com | Annalee Armstrong

The biotech industry is already feeling the regulatory impact of dramatic staff cuts at the FDA, according to a letter sent by executives, patient advocates and investors to Sen. Bill Cassidy (R-LA). Cassidy oversees the Health, Education, Labor, and Pensions (HELP) Committee that conducted the hearings for new FDA chief Marty Makary. The executives urged the senator toward action to ensure the agency can continue its core mission.
Trump Tariff Pause Sparks Late-Day Rally for Pharma Stocks-But Not All

2 weeks ago | biospace.com | Annalee Armstrong

The threat of tariffs has put the pharma industry through the wringer this week. On Wednesday, a week after instituting widespread tariffs and a day after promising that “major” tariffs were headed for pharma specifically, President Donald Trump abruptly paused most newly enacted import taxes, sparking a rally across the markets. Eli Lilly’s shares, which have declined 13% in one month, perfectly illustrated the one-day trend.